SCHEDULE: RA Capital Boosts Equillium Stake to 9.9%

RA Capital Management and its affiliates have reported a 9.9% beneficial ownership stake in Equillium, Inc., primarily through shared voting and dispositive power.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The Reporting Persons collectively beneficially own 6,480,209 shares of Equillium, Inc. common stock.
• This represents 9.9% of the outstanding common stock.
• Ownership includes 3,096,336 direct shares and pre-funded warrants exercisable for up to 17,698,593 shares.
• A "Beneficial Ownership Blocker" provision in the pre-funded warrants precludes exercise to the extent that, following exercise, the Fund and its affiliates would own more than 9.9% of the common stock outstanding.
• The 9.9% beneficial ownership percentage is based on 60,893,283 shares outstanding as of November 10, 2025, plus 1,179,508 shares from a private placement on March 13, 2026, and 3,383,873 shares issuable upon exercise of the pre-funded warrants.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a reputable healthcare fund like RA Capital can instill investor confidence, despite the technical limitation of the beneficial ownership blocker.

Positives

• Significant institutional investment from RA Capital Management, a specialized healthcare investor, signals confidence in Equillium, Inc.'s prospects.
• The substantial stake (9.9%) indicates a strong commitment from a prominent biotech-focused fund.

Negatives

• The "Beneficial Ownership Blocker" provision in the pre-funded warrants limits RA Capital's immediate ability to increase its beneficial ownership beyond 9.9% through warrant exercise, potentially capping their influence without further open market purchases.

Risks

• The presence of a "Beneficial Ownership Blocker" on a significant portion of held warrants (17,698,593 shares) means that RA Capital's ability to increase its beneficial ownership percentage above 9.9% is restricted, which could limit their flexibility in future investment strategies or influence over the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that RA Capital Management is a well-known healthcare and life sciences investment firm. Their significant stake in Equillium, a biotechnology company, suggests a strategic interest in the company's pipeline or market position within the competitive biotech sector. Such an investment from a specialized fund can often be seen as a vote of confidence in the company's long-term prospects, potentially influencing other institutional investors.

Comparison to Industry Standards

• StockSavvy.ai observes that a 9.9% stake by a specialized healthcare fund like RA Capital is a substantial position, often indicative of a high-conviction investment.
• While direct comparisons to specific companies or projects are not provided in this filing, such an ownership level is generally considered a significant institutional endorsement within the biotech industry, where early-stage companies often rely on strong institutional backing.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially signaling confidence in the company's future.
• Company Management: The presence of a significant institutional investor like RA Capital may lead to increased scrutiny or engagement regarding strategic decisions.

Key Dates

Keywords

Equillium, RA Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Healthcare Investment, Institutional Investor, EQ, Warrants